Coherus Oncology Reports Q3 2026 Results with Revenue Growth and Strategic Cost Reductions
Coherus Oncology (CHRS) reported third-quarter 2026 financial results characterized by a strategic shift toward clinical priorities. The company achieved $14 million in LOQTORZI net revenue, marking a 25% increase compared to the same period last year. To improve capital efficiency, Coherus implemented a 30% headcount reduction and realized quarterly cost savings of $6 million to $7 million through organizational rightsizing. Despite these efficiencies, the company faces liquidity challenges, reporting $83.6 million in cash and investments as of September 30, 2026. Management noted that without additional milestones or deals, the current cash runway is less than 12 months. The company also revised its full-year 2026 revenue outlook to a range of $54 million to $57 million due to localized patient flow dynamics.
Tickers: $CHRS
Topics: cash burn cost reduction debt refinancing guidance revision layoffs revenue growth